TY - JOUR
T1 - Algorithm for the treatment of schizophrenia in Japan
AU - Sato, M.
AU - Nakane, N.
AU - Hayashida, M.
AU - Koshino, Y.
AU - Uchimura, H.
AU - Tsutsumi, T.
AU - Koyama, T.
AU - Kusumi, I.
AU - Akiyama, K.
AU - Saito, H.
AU - Saijo, T.
AU - Ito, C.
AU - Kubota, Y.
AU - Nishikawa, T.
AU - Kuroda, Y.
AU - Hamamura, T.
AU - Fujiwara, Y.
AU - Higuchi, T.
AU - Yamawaki, S.
PY - 1999/12
Y1 - 1999/12
N2 - Evidence-based psychopharmacological algorithms for the treatment of patients with schizophrenia have been developed in many countries in the last decade. While it would be of interest to consider a common algorithm based on international consensus, algorithms and information on antipsychotics available in each country are limited. Inspired by the algorithm generated by the International Psychopharmacology Algorithm (IPA) Project, this algorithm for the treatment of schizophrenia has been developed by the Japan Psychopharmacology Algorithm (JPA) Project. New antipsychotics, such as clozapine, olanzapine and quetiapine, are excluded from this algorithm, being currently unavailable in Japan. In the end there was no essential difference between the algorithms for the treatment of acute schizophrenic episodes. However, combined use of antipsychotics appears to be more common in Japan and the adjunctive use of L-DOPS or thyrotropin-releasing hormone is included in the JPA algorithm for the treatment of drug-refractory schizophrenia.
AB - Evidence-based psychopharmacological algorithms for the treatment of patients with schizophrenia have been developed in many countries in the last decade. While it would be of interest to consider a common algorithm based on international consensus, algorithms and information on antipsychotics available in each country are limited. Inspired by the algorithm generated by the International Psychopharmacology Algorithm (IPA) Project, this algorithm for the treatment of schizophrenia has been developed by the Japan Psychopharmacology Algorithm (JPA) Project. New antipsychotics, such as clozapine, olanzapine and quetiapine, are excluded from this algorithm, being currently unavailable in Japan. In the end there was no essential difference between the algorithms for the treatment of acute schizophrenic episodes. However, combined use of antipsychotics appears to be more common in Japan and the adjunctive use of L-DOPS or thyrotropin-releasing hormone is included in the JPA algorithm for the treatment of drug-refractory schizophrenia.
KW - Acute schizophrenic episode
KW - International Psychopharmacology Algorithm
KW - Japan Psychomarcology Algorithm Project
KW - Therapy-resistant schizophrenia
KW - Treatment algorithm
UR - http://www.scopus.com/inward/record.url?scp=0033386592&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033386592&partnerID=8YFLogxK
U2 - 10.3109/13651509909068395
DO - 10.3109/13651509909068395
M3 - Article
AN - SCOPUS:0033386592
SN - 1365-1501
VL - 3
SP - 271
EP - 276
JO - International Journal of Psychiatry in Clinical Practice
JF - International Journal of Psychiatry in Clinical Practice
IS - 4
ER -
